Ventyx Biosciences Stock Analysis

VTYX Stock  USD 2.88  0.01  0.35%   
Ventyx Biosciences is undervalued with Real Value of 15.78 and Target Price of 54.6. The main objective of Ventyx Biosciences stock analysis is to determine its intrinsic value, which is an estimate of what Ventyx Biosciences is worth, separate from its market price. There are two main types of Ventyx Biosciences' stock analysis: fundamental analysis and technical analysis.
The Ventyx Biosciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Ventyx Biosciences is usually not traded on Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day. Ventyx Stock trading window is adjusted to America/New York timezone.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Ventyx Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For more information on how to buy Ventyx Stock please use our How to Invest in Ventyx Biosciences guide.

Ventyx Stock Analysis Notes

About 95.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 1.34. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Ventyx Biosciences recorded a loss per share of 3.24. The entity had not issued any dividends in recent years. Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California. Ventyx Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 34 people. For more information please call Raju Mohan at 760 593 4832 or visit https://ventyxbio.com.

Ventyx Biosciences Investment Alerts

Ventyx Biosciences generated a negative expected return over the last 90 days
Ventyx Biosciences has high historical volatility and very poor performance
Net Loss for the year was (192.96 M) with profit before overhead, payroll, taxes, and interest of 0.
Ventyx Biosciences currently holds about 250.45 M in cash with (166.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.92, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Ventyx Biosciences has a frail financial position based on the latest SEC disclosures
Over 95.0% of the company outstanding shares are owned by institutional investors
Latest headline from benzinga.com: VENTYX INVESTIGATION ANNOUNCEMENT Ventyx Stock Drops 20, Investors are Urged to Contact BFA Law about the Investigation into the Companys Board

Ventyx Biosciences Upcoming and Recent Events

Earnings reports are used by Ventyx Biosciences to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
28th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Ventyx Largest EPS Surprises

Earnings surprises can significantly impact Ventyx Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-08-15
2022-06-30-0.45-0.390.0613 
2024-05-09
2024-03-31-0.69-0.620.0710 
2022-05-12
2022-03-31-0.52-0.450.0713 
View All Earnings Estimates

Ventyx Biosciences Environmental, Social, and Governance (ESG) Scores

Ventyx Biosciences' ESG score is a quantitative measure that evaluates Ventyx Biosciences' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Ventyx Biosciences' operations that may have significant financial implications and affect Ventyx Biosciences' stock price as well as guide investors towards more socially responsible investments.

Ventyx Biosciences Thematic Classifications

In addition to having Ventyx Biosciences stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products Idea
Pharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Ventyx Stock Institutional Investors

Shares
Goldman Sachs Group Inc2024-03-31
1.7 M
Octagon Capital Advisors Lp2024-03-31
1.5 M
Morgan Stanley - Brokerage Accounts2024-03-31
1.3 M
Opaleye Management Inc2024-03-31
1.3 M
Adage Capital Partners Gp Llc2024-03-31
1.3 M
Parkman Healthcare Partners Llc2024-03-31
1.2 M
Geode Capital Management, Llc2024-03-31
1.1 M
Sphera Funds Management Ltd.2024-03-31
992.7 K
Jpmorgan Chase & Co2024-03-31
953.5 K
Blackrock Inc2024-03-31
3.7 M
Vanguard Group Inc2024-03-31
3.7 M
Note, although Ventyx Biosciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Ventyx Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 203.04 M.

Ventyx Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.69)(0.72)
Return On Capital Employed(0.80)(0.76)
Return On Assets(0.69)(0.73)
Return On Equity(0.79)(0.75)

Management Efficiency

Ventyx Biosciences has return on total asset (ROA) of (0.3591) % which means that it has lost $0.3591 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5676) %, meaning that it created substantial loss on money invested by shareholders. Ventyx Biosciences' management efficiency ratios could be used to measure how well Ventyx Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.72 in 2024. Return On Capital Employed is likely to rise to -0.76 in 2024. At this time, Ventyx Biosciences' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 18.2 M in 2024, whereas Total Assets are likely to drop slightly above 207.1 M in 2024.
Last ReportedProjected for Next Year
Book Value Per Share 4.17  4.37 
Tangible Book Value Per Share 4.17  2.52 
Enterprise Value Over EBITDA(0.52)(0.54)
Price Book Value Ratio 0.59  0.62 
Enterprise Value Multiple(0.52)(0.54)
Price Fair Value 0.59  0.62 
Enterprise Value105.5 M100.3 M
The analysis of Ventyx Biosciences' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Ventyx Biosciences' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Ventyx Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
0.578
Return On Assets
(0.36)
Return On Equity
(0.57)

Technical Drivers

As of the 18th of June 2024, Ventyx Biosciences has the Coefficient Of Variation of (2,511), variance of 91.68, and Risk Adjusted Performance of (0.02). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Ventyx Biosciences, as well as the relationship between them.

Ventyx Biosciences Price Movement Analysis

Execute Study
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Ventyx Biosciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Ventyx Biosciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Ventyx Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ventyx Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ventyx Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ventyx Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Ventyx Biosciences Predictive Daily Indicators

Ventyx Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ventyx Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Ventyx Biosciences Corporate Filings

F4
11th of June 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
7th of June 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
6th of June 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
5th of June 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F3
17th of May 2024
The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock
ViewVerify
8K
16th of May 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
9th of May 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
1st of May 2024
Other Reports
ViewVerify

Ventyx Biosciences Forecast Models

Ventyx Biosciences' time-series forecasting models are one of many Ventyx Biosciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ventyx Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Ventyx Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Ventyx Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ventyx shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Ventyx Biosciences. By using and applying Ventyx Stock analysis, traders can create a robust methodology for identifying Ventyx entry and exit points for their positions.
Last ReportedProjected for Next Year

Current Ventyx Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ventyx analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ventyx analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
54.6Strong Buy10Odds
Ventyx Biosciences current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Ventyx analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Ventyx stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Ventyx Biosciences, talking to its executives and customers, or listening to Ventyx conference calls.
Ventyx Analyst Advice Details

Ventyx Stock Analysis Indicators

Ventyx Biosciences stock analysis indicators help investors evaluate how Ventyx Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Ventyx Biosciences shares will generate the highest return on investment. By understating and applying Ventyx Biosciences stock analysis, traders can identify Ventyx Biosciences position entry and exit signals to maximize returns.
Begin Period Cash Flow64.8 M
Common Stock Shares Outstanding58.5 M
Total Stockholder Equity243.9 M
Property Plant And Equipment Net12.3 M
Cash And Short Term Investments252.2 M
Cash51.6 M
Accounts Payable5.8 M
Net Debt-39.1 M
50 Day M A4.3679
Total Current Liabilities22.3 M
Other Operating Expenses205.5 M
Non Current Assets Total13.3 M
Non Currrent Assets Other1.1 M
Stock Based Compensation28.6 M

Additional Tools for Ventyx Stock Analysis

When running Ventyx Biosciences' price analysis, check to measure Ventyx Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ventyx Biosciences is operating at the current time. Most of Ventyx Biosciences' value examination focuses on studying past and present price action to predict the probability of Ventyx Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ventyx Biosciences' price. Additionally, you may evaluate how the addition of Ventyx Biosciences to your portfolios can decrease your overall portfolio volatility.